Fullerene-based Low Toxic Nanocationite Particles (Porphyrin Adducts of Cyclohexyl Fullerene-C60) to Treat Hypoxia-induced Mitochondrial Dysfunction in Mammalian Heart Muscle

Archives of Medical Research

Volumn 39, Issue 6, 2008, Pages 549-559

  Amirshahi, Nima ^a   Alyautdin, Renad N ^a   Sarkar, Saeed ^b   Rezayat, Seyed M ^b   Orlova, Marina A ^c   Trushkov, Igor V ^c   Buchachenko, Anatoly L ^d   Kuznetsov, Dmitry A ^d  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

^d SEMENOV INSTITUTE OF CHEMICAL PHYSICS   (Russian Federation)

Author keywords

25Mg2+ magnetic isotope effect; ATP hyperproduction; Myocardium hypoxia; Porphyrin fullerenes

Indexed keywords

ADENOSINE TRIPHOSPHATE; MAGNESIUM; NANOPARTICLE; OXYGEN; PORPHYLLEREN MC16 [MAGNESIUM];

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ENERGY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; HEART MUSCLE; HEART MUSCLE CELL; HYPOXIA; LD 50; MALE; NONHUMAN; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANOXIA; CATIONS; FULLERENES; HEART; MALE; MICROSCOPY, ATOMIC FORCE; MITOCHONDRIA, HEART; NANOPARTICLES; RATS; RATS, WISTAR;

EID: 47749136588     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2008.05.007     Document Type: Article

References (47)

1. Sarkar S, Rezayat SM, Buchachenko AL, Kuznetsov DA, Orlova MA, Yurovskaya MA, et al. New water soluble porphylleren compounds. European Union Patent No. 07009882.7/EP07009882 (Reg: Munich, Germany) 2007.
2. Sarkar S, Rezayat SM, Buchachenko AL, Kuznetsov DA, Orlova MA, Yurovskaya MA, et al. Use of a magnesium isotope for treating hypoxia and a medicament comprising the same. European Union Patent No. 07009881.9/EP07009881 (Reg: Munich, Germany) 2007.
3. Wallace K.B., and Starkov A.A. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol 40 (2000) 353-388
4. Souid A.K., Tacka K.A., Galvan K.A., and Penefsky H.S. Immediate effects of anticancer drugs on mitochondrial oxygen consumption. Biochem Pharmacol 66 (2003) 977-987
5. Wallace K.B. Doxorubicin-induced cardiac mitochondriopathy. Pharmacol Toxicol 93 (2003) 105-115
6. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., and Walter P. Molecular Biology of the Cell. New York: Garland Science Publishers (2002)
7. Waugh T, Telashima H. Mitochondria. Research Triangle Publication. Raleigh-Durham, NC;2004.
8. 26Mg isotope effect in mitochondrial ADP phosphorylation. Cell Biochem Biophys 43 (2005) 243-252
9. Buchachenko A.L., Kuznetsov D.A., Arkhangelsky S.E., Orlova M.A., and Markarian A.A. Spin biochemistry: intramitochondrial nucleotide phosphorylation is a magnesium nuclear spin controlled process. Mitochondrion 5 (2005) 67-70
10. Buchachenko A.L., Kuznetsov D.A., Orlova M.A., and Markarian A.A. Magnetic isotope effect of magnesium in phosphoglycerate kinase phosphorylation. Proc Natl Acad Sci USA 102 (2005) 10793-10797
11. Buchachenko A.L., Kuznetsov D.A., Breslavskaya N.N., and Orlova M.A. Magnesium isotope effects in enzymatic phophorylation. J Phys Chem Series B 112 (2008) 708-719
12. Kano K. Molecular complexes of water-soluble porphyrins. J Porph Phthalocynines 8 (2004) 148-155
13. Hudson R., Mallroy C., Darnell S., and Smith K.M. Porphyrin conjugates in photoimmunotherapy. Br J Cancer 93 (2006) 1442-1450
14. Pawar R., Avramoff A., and Domb A.J. Nanoparticles for crossing biological membranes. In: Kumar C.S.S.R. (Ed). Biological and Pharmacological Nanomaterials (2007), Wiley-VCH, Baton Rouge 349-393
15. Tyler D.D., and Gonze J. The preparation of heart mitochondria from laboratory animals. Meth Enzymol 10 (1967) 75-122
16. Gergely M., and Lakatos I. Molecular and Cellular Cardiology. Alba Regia: Budapest-Szeged (1999)
17. Mahatoo R. Biological membranes and barriers. In: Telashima I., and Waugh J.A. (Eds). Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids (2005), CRC Press, Boca Raton, FL 241-260
18. Bradford M.M. An improved colorimetric technique for protein measurement. Analyt Biochem 72 (1976) 348-354
19. 59Fe-labeled organelle supplemented with an electron microscopic track study. Bull Exp Biol Med 58 (1997) 668-674
20. Piotrovsky L.B., and Kiselyov O.I. Biological Effects of Fullerenes (2008), Research Triangle Press, Raleigh-Durham, NC
21. The Nanofinder-S16E: Laser Confocal Microscopy-Raman Spectroscopy Unit. Technical Manual. Nanofinder Co. Publ. Minsk-Grodno (Byelorussia);2006.
22. Kuznetsov D.A., Govorkov A.V., Zavijalov N.V., Silbileva T.M., Richter V., and Drawczek J.A. Fast estimation of ATP/ADP ratio as a special step in pharmacological and toxicological studies using the cell-free translation system. J Biochem Biophys Meth 13 (1986) 53-56
23. Lo L.W., Koch C.J., and Wilson D.F. Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra-(4-carboxyphenyl)porphine: a phosphor with general application for measuring oxygen concentration in biological systems. Anal Biochem 236 (1996) 153-160
24. Vinogradov S.A., and Wilson D.F. Metallotetrabenzoporphyrins. New phosphorescent probes for oxygen measurements. J Chem Soc Perkin Trans 2 (1995) 103-111
25. Radioimmunoassays and Related Analytical Techniques. Technical manual by Bio-Rad. Bio-Rad Press: Durham-St. Petersburg;2006.
26. Bielka H., Lottmeyer K., Roetzsch K., Schumm O., Wietzel D., and Rauch M. The human blood cells biomass in a drug metabolites uptake screening. Clin Exp Pathol 16 (1996) 444-458
27. Benet L.Z., and Galeazzi R.L. Determination of the steady-state volume drug distribution. J Pharmacol Sci 68 (1979) 1071-1074
28. Morgan D.J., and Smallwood R.A. Clinical significance of pharmacokinetic models of hepatic elimination. Clin Pharmacokinet 18 (1990) 61-76
29. Birkett D.J. Pharmacokinetics Made Easy (1998), McGraw-Hill, Sydney-Melbourne
30. 60-fullerene molecule toxic?. Fullerenes, Nanotubes, Carbon Nanostructures 13 (2005) 363-376
31. 60 dyads with high ability to form photo-induced charge-separated state as novel sensitizers for photodynamic therapy. Photochem Photobiol 81 (2005) 891-897
32. Lin Y.L., Lei H.Y., Chou C.K., and Liu H.S. Light-independent inactivation of dengue-2 virus by carboxyfullerene C3 isomer. Virology 275 (2000) 258-262
33. Mashino T., Okuda K., Hirota T., Hirobe M., Nagano T., and Mochizuki M. Inhibition of E. coli grown by fullerene derivatives and inhibition mechanism. Bioorg Med Chem Lett 9 (1999) 2959-2962
34. Suarez M., Verdecia Y., Illescas B., Martines-Alvarez R., Alvarez A., Ochoa E., et al. Synthesis and study of novel fulleropyrrolidines bearing biologically active 1,4-dihydropyridines. Tetrahedron 59 (2003) 9179-9186
35. Pantarotto D., Tagmatarchis N., Bianco A., and Prato M. Synthesis and biological properties of fullerene-containing amino acids and peptides. Minerva Med Chem 4 (2004) 805-814
36. Tabata Y., and Ikada Y. Biological functions of fullerenes. Pure Appl Chem 71 (1999) 2047-2053
37. Baierl T., and Siedel A. The in vitro effects of fullerene black on immunofunctions of macrophages. Fullerene Sci Technol 4 (1996) 1073-1085
38. Mellul M. Cosmetic make-up composition containing a fullerene or mixture of fullerenes. US Patent No. 561202 (1997)
39. Leone J.E., and Narayanan P.V. Catheter system having fullerenes and method. US Patent No. 6468244 (2002)
40. Schmitt L., Ludwig M., Gaub H.E., and Tampe R. A metal-chelating microscopy tip as a new toolbox for single-molecule experiments by atomic force microscopy. Biophys J 78 (2000) 3275-3285
41. Fotiadis D., Scheuring S., Müller S.A., Engel A., and Müller D.J. Imaging and manipulation of biological structures with the AFM. Micron 33 (2002) 385-397
42. Kumar M.N.V.R. Nano and microparticles as controlled drug delivery devices. J Pharm Pharmaceut Sci 3 (2000) 234-258
43. Pankhurst Q.A., Connolly J., Jones S.K., and Dobson J. Application of magnetic nanoparticles in biomedicine. J Phys (Series D: Appl Physics) 36 (2003) R167-R181
44. Kubik T., Bogunia K., and Sugisaka M. Nanotechnology on duty in medicinal applications. Curr Pharm Biotechnol 6 (2005) 17-33
45. Gad S.C. Drug Safety Evaluation (2002), John Wiley & Sons, New York
46. Hoft F.H., Hohlfeld I.B., and Salata O.V. Nanoparticles: known and unknown risks. J Nanobiotechnol 2 (2004) 12-24
47. Hong R., Fisher N.O., Verma A., Goodman C.M., Emrick T., and Rotello V.M. Control of protein structure and function through surface recognition by scaffolds. J Am Chem Soc 126 (2004) 739-143